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Neurodegenerative disorders such as 
Alzheimer disease, amyotrophic lateral 
sclerosis (ALS), and Parkinson disease are 
characterized by the selective loss of spe-
cific neuronal subtypes. While the precise 
mechanisms underlying neuronal dys-
function and subtype specificity remain 
the subject of intense study, the cellular 
environment in which degenerating neu-
rons reside has been shown to be an inte-
gral part of the disease. Converging lines 
of evidence highlight the crucial role of glia 
in setting the pace of, and perhaps in some 
instances initiating, neurodegeneration.
ALS disease models, especially 
hSOD1G93A transgenic mice, have been 
particularly influential in establishing the 
conceptual framework of cellular auton-
omy and neurodegeneration. Astrocytes, 
microglia, and oligodendrocytes all play 
different roles in neuronal death; selec-
tive lineage-specific downregulation of 
mutant SOD1 transgene in ALS mouse 
models results in altered disease onset 
and/or progression. The development of 
embryonic stem cell (ESC)-derived neural 
cell co-culture systems has further enabled 
an exploration of the role of glia on neuro-
nal survival at the molecular level. Several 
groups have independently established 
that both rodent hSOD1G93A astroglia1,2 
and astrocytes derived at postmortem 
from human mutant SOD1 and sporadic 
ALS cases are toxic to mouse ESC-derived 
motor neurons (MNs).
Even though mutant SOD1 cases con-
stitute a relatively small fraction of ALS 
pathobiology, reactive glia are a defining 
feature of all neurodegenerative disor-
ders. Astrocytes are in constant signaling 
exchange with the surrounding cells, 
acquiring a number of dynamic pheno-
typic changes in response to different stress 
stimuli broadly defined as “reactive astro-
glia”. Against this background, several 
key questions emerge. These include: are 
there disease or mutation specific reactive 
properties of astrocytes?; are there aspects 
of reactive gliosis common to all neurode-
generative conditions?; and which, if any, 
of these properties are glia-intrinsic, or are 
they secondary to neuronal degeneration?
Dissection of these pathways requires a 
better understanding of glial diversity and 
function, a field that has been mostly left 
in the shadow of a neuro-centric focus on 
neurodegeneration. The advent of induced 
human pluripotent stem cells (iPSCs) now 
provides the opportunity to build human 
cellular platforms that will allow us to 
directly address these questions. Directed-
differentiation protocols permit the gener-
ation of near-homogenous populations of 
functional human neurones and glia, where 
the effect of particular mutations and/or 
stressors can be studied both in isolation 
and in co-culture. Using patient-derived 
iPSCs, we and others have recently shown 
that a mutation in TARDBP encoding 
TAR DNA-binding protein 43 (TDP-43) 
associated with familial ALS underlies 
a cell-autonomous vulnerability both in 
isolated motor neurones3,4 and astrocytes.5 
Importantly, these iPSC-derived models 
recapitulate key cellular and biochemical 
aspects of the TDP-43 proteinopathies 
that account for 95% of ALS and 55% of 
frontotemporal dementia (FTD) cases.
Is there a contribution of mutant 
TDP-43 astrocytes to human ALS pathol-
ogy? Our in vitro co-culture experiments 
with real-time single-cell longitudinal 
survival analysis did not reveal an adverse 
survival effect of mutant TDP-43 astro-
cytes on either WT or MT human MNs, 
whereas hSOD1G93A transgenic mouse glia 
were toxic to both, as predicted.5 These 
contrasting findings may point to a mech-
anistic divergence of TDP-43 and SOD1 
associated toxicity, or may simply reflect 
that in vitro differentiation of astrocytes 
from human PSCs in the absence of 
degenerating neurons does not capture the 
full spectrum of in vivo reactive proper-
ties. Indirect support of such an idea is 
provided by a recent study using trans-
genic rat models with selective neuronal 
lineage expression of mutant TDP-43 or 
fused in sarcoma (FUS), another RNA-
binding protein linked to ALS and FTD, 
that identified lipocalin 2 as a neurotoxic 
factor induced in reactive astrocytes in 
response to neurodegeneration. This event 
is independent of the expression of the 
mutant proteins in the glial lineage.6
Improved understanding of the role of 
astrocytes in neurodegeneration requires 
multiple experimental—in vitro and in 
vivo—approaches. First, enriched in vitro 
astrocyte differentiation platforms from 
human PSCs should not only achieve the 
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expression of specific lineage markers, 
both for glial restricted progenitors and 
differentiated progeny, but also include 
detailed functional characterization, such 
as glutamate uptake, induction of syn-
aptogenesis, and propagation of calcium 
waves.5 The relevance of regional hetero-
geneity is uncertain, as is the perennial 
question of whether one can ever truly 
replicate the complexity inherent in an 
aged brain in an essentially develop-
mental in vitro system. Consequently, in 
vivo transplantation and/or slice culture 
explant studies are necessary to extend 
the in vitro observations of function. 
Second, comparative transcriptomic and 
proteomic approaches—ideally with refer-
ence to pathological disease samples—are 
necessary to delineate reactive properties 
of glia under different disease settings. 
The interplay between neuronal degenera-
tion and glial response has recently been 
addressed in a genome-wide study uncov-
ering distinct as well as shared pathways 
in reactive gliosis caused by inflammation, 
stroke, and hSOD1G93A trangenic astro-
glial-mediated toxicity.7
It is now clear that glia can substan-
tially affect the survival of neurons in dis-
ease states both by acquisition of reactive 
properties that are toxic and also through 
impairment of their normal physiologi-
cal roles. Therefore, modulating astrocyte 
behavior by promotion of their neuropro-
tective functions8 and/or limiting their 
neurotoxic properties offers a new thera-
peutic strategy for neuroprotection in neu-
rodegenerative disorders.
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